Chemical Biology Research Center, School of Pharmaceutical Sciences, Wenzhou Medical University, Wenzhou, Zhejiang, 325035, China.
Department of Cardiology and Medical Research Center, the First Affiliated Hospital, Wenzhou Medical University, Wenzhou, Zhejiang, 325035, China.
Cell Death Differ. 2023 May;30(5):1184-1197. doi: 10.1038/s41418-023-01147-8. Epub 2023 Mar 13.
Doublecortin-like kinase 1 (DCLK1), a microtubule-associated protein kinase, is involved in neurogenesis, and its levels are elevated in various human cancers. Recent studies suggest that DCLK1 may relate to inflammatory responses in the mouse model of colitis. However, cellular pathways engaged by DCLK1, and potential substrates of the kinase remain undefined. To understand how DCLK1 regulates inflammatory responses, we utilized the well-established lipopolysaccharide (LPS)-stimulated macrophages and mouse model. Through a range of macrophage-based and cell-free platforms, we discovered that DCLK1 binds directly with the inhibitor of κB kinase β (IKKβ) and induces IKKβ phosphorylation on Ser177/181 to initiate nuclear factor-κB (NF-κB) pathway. Deficiency in DCLK1, achieved by silencing or through pharmacological inhibition, prevented LPS-induced NF-κB activation and cytokine production in macrophages. We further show that mice with myeloid-specific DCLK1 knockout or DCLK1 inhibitor treatment are protected against LPS-induced acute lung injury and septic death. Our studies report a novel functional role of macrophage DCLK1 as a direct IKKβ regulator in inflammatory signaling and suggest targeted therapy against DCLK1 for inflammatory diseases.
双皮质醇激酶 1(DCLK1)是一种微管相关蛋白激酶,参与神经发生,其水平在各种人类癌症中升高。最近的研究表明,DCLK1 可能与结肠炎的小鼠模型中的炎症反应有关。然而,DCLK1 参与的细胞途径和激酶的潜在底物仍未确定。为了了解 DCLK1 如何调节炎症反应,我们利用了成熟的脂多糖(LPS)刺激的巨噬细胞和小鼠模型。通过一系列基于巨噬细胞的和无细胞平台,我们发现 DCLK1 直接与核因子-κB(NF-κB)途径的 IκB 激酶β(IKKβ)结合,并诱导 IKKβ 在丝氨酸 177/181 上磷酸化,从而启动 NF-κB 途径。通过沉默或通过药理学抑制来实现 DCLK1 的缺乏,可防止 LPS 诱导的巨噬细胞中 NF-κB 的激活和细胞因子的产生。我们进一步表明,髓样细胞特异性 DCLK1 敲除或 DCLK1 抑制剂治疗的小鼠可防止 LPS 诱导的急性肺损伤和败血症死亡。我们的研究报告了巨噬细胞 DCLK1 作为炎症信号传导中直接 IKKβ 调节剂的新功能作用,并表明针对 DCLK1 的靶向治疗可用于炎症性疾病。